Author

Nanne Aben

The Netherlands Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioinformatics· 3 Cancer Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Research Focus:differential expression· 3 Research Focus:benchmarking· 2 Assay:proteomics· 2 Approach:statistical model· 2 Approach:benchmark study· 1

Frequent Co-Authors

Magali MichautiD· 4 shared Lodewyk F.A. WesselsiD· 3 shared Clara AlsinetiD· 2 shared David J. AdamsiD· 2 shared Evert BosdriesziD· 2 shared Gergana Bounova· 2 shared Theodoros I. RoumeliotisiD· 2 shared Ultan McDermottiD· 2 shared

Activity by Year

2017-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioinformatics

Magali MichautORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction

Michael P. Menden, Dennis Y.Q. Wang, Mike J. Mason, Bence Szalai, Krishna C. Bulusu, Yuanfang Guan, Thomas Von Yu, Jaewoo Kang, Minji Jeon, Russell D. Wolfinger, Tin Nguyen, Mikhail Zaslavskiy, Jordi Abante, Bárbara Schmitz‐Abecassis, Nanne Aben, , Denis Fourches

The paper presents a large-scale cancer pharmacogenomic screen with 11,576 experiments on 910 drug combinations across 85 cancer cell lines, enabling crowd-sourced prediction of synergistic drug pairs and biomarkers.

Nature Communications · Jun 17, 2019Peer-reviewedBioinformatics

Identifying biomarkers of anti-cancer drug synergy using multi-task learning

Nanne Aben, Julian R. de Ruiter, Evert Bosdriesz, Yongsoo Kim, Gergana Bounova, Daniël J. Vis, Lodewyk F.A. Wessels, Magali Michaut

The paper uses multi-task learning to identify biomarkers of anti-cancer drug synergy using low-sample-size drug combination data from 85 cell lines and 167 drug combinations.

bioRxiv · Aug 23, 2018 · PreprintBioinformatics

iTOP: Inferring the Topology of Omics Data

Nanne Aben, Johan A. Westerhuis, Yipeng Song, Henk A. L. Kiers, Magali Michaut, Age K. Smilde, Lodewyk F.A. Wessels

iTOP infers relationships between omics datasets using partial matrix correlations and identifies gene expression as a mediator between other datasets and drug response.

Bioinformatics · Aug 7, 2018Peer-reviewedBioinformatics

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I. Roumeliotis, Martin Del Castillo Velasco-Herrera, Jérémie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, , David J. Adams

bioRxiv · Sep 28, 2017 · PreprintCancer Biology

Genomic determinants of protein abundance variation in colorectal cancer cells

Theodoros I. Roumeliotis, Steven P. Williams, Emanuel Gonçalves, Clara Alsinet, Martin Del Castillo Velasco‐Herrera, Nanne Aben, Fatemeh Zamanzad Ghavidel, Magali Michaut, Michaël Schubert, Stacey Price, James C. Wright, Lu Yu, Mi Yang, Rodrigo Dienstmann, Justin Guinney, , Jyoti Sharma Choudhary

The paper quantifies proteomic and genomic variation in colorectal cancer cell lines to understand how mutations affect protein levels and drug responses.

Cell Reports · Aug 1, 2017Peer-reviewedSystems Biology